110 related articles for article (PubMed ID: 21484565)
41. Daidzein, its effects on impaired glucose and lipid metabolism and vascular inflammation associated with type 2 diabetes.
Das D; Sarkar S; Bordoloi J; Wann SB; Kalita J; Manna P
Biofactors; 2018 Sep; 44(5):407-417. PubMed ID: 30191623
[TBL] [Abstract][Full Text] [Related]
42. A review of the molecular pathways mediating the improvement in diabetes mellitus following caloric restriction.
Yaribeygi H; Atkin SL; Ramezani M; Sahebkar A
J Cell Physiol; 2019 Jun; 234(6):8436-8442. PubMed ID: 30426486
[TBL] [Abstract][Full Text] [Related]
43. Targeting ageing and preventing organ degeneration with metformin.
Sunjaya AP; Sunjaya AF
Diabetes Metab; 2021 Feb; 47(1):101203. PubMed ID: 33148437
[TBL] [Abstract][Full Text] [Related]
44. Diabetes mellitus and endometrial carcinoma: Risk factors and etiological links.
Wang Y; Zeng X; Tan J; Xu Y; Yi C
Medicine (Baltimore); 2022 Aug; 101(34):e30299. PubMed ID: 36042597
[TBL] [Abstract][Full Text] [Related]
45. IL-6 signalling pathways and the development of type 2 diabetes.
Akbari M; Hassan-Zadeh V
Inflammopharmacology; 2018 Jun; 26(3):685-698. PubMed ID: 29508109
[TBL] [Abstract][Full Text] [Related]
46. Non-immune-based treatment for type 1 diabetes: the way to go?
Rigby MR
Lancet Diabetes Endocrinol; 2014 Sep; 2(9):681-2. PubMed ID: 24997558
[No Abstract] [Full Text] [Related]
47. Incretins and thiazolidinediones in glucose homeostasis and cancer: role of common polymorphisms.
Arora S; Mehrotra A; Gulati SC
Cancer Lett; 2012 Oct; 323(2):128-34. PubMed ID: 22521548
[TBL] [Abstract][Full Text] [Related]
48. Wired on sugar: the role of the CNS in the regulation of glucose homeostasis.
Grayson BE; Seeley RJ; Sandoval DA
Nat Rev Neurosci; 2013 Jan; 14(1):24-37. PubMed ID: 23232606
[TBL] [Abstract][Full Text] [Related]
49. Strategies of Unloading the Failing Heart from Metabolic Stress.
Koutroumpakis E; Jozwik B; Aguilar D; Taegtmeyer H
Am J Med; 2020 Mar; 133(3):290-296. PubMed ID: 31520618
[TBL] [Abstract][Full Text] [Related]
50. Type 2 Diabetes and Breast Cancer: The Interplay between Impaired Glucose Metabolism and Oxidant Stress.
Ferroni P; Riondino S; Buonomo O; Palmirotta R; Guadagni F; Roselli M
Oxid Med Cell Longev; 2015; 2015():183928. PubMed ID: 26171112
[TBL] [Abstract][Full Text] [Related]
51. Benefits of healthy adipose tissue in the treatment of diabetes.
Gunawardana SC
World J Diabetes; 2014 Aug; 5(4):420-30. PubMed ID: 25126390
[TBL] [Abstract][Full Text] [Related]
52. Therapeutic value of brown adipose tissue: Correcting metabolic disease through generating healthy fat.
Gunawardana SC
Adipocyte; 2012 Oct; 1(4):250-255. PubMed ID: 23700541
[TBL] [Abstract][Full Text] [Related]
53. Early differentiation patterning of mouse embryonic stem cells in response to variations in alginate substrate stiffness.
Candiello J; Singh SS; Task K; Kumta PN; Banerjee I
J Biol Eng; 2013 Apr; 7(1):9. PubMed ID: 23570553
[TBL] [Abstract][Full Text] [Related]
54. SGLT2 inhibition in diabetes mellitus: rationale and clinical prospects.
Ferrannini E; Solini A
Nat Rev Endocrinol; 2012 Feb; 8(8):495-502. PubMed ID: 22310849
[TBL] [Abstract][Full Text] [Related]
55. Targeting type 2 diabetes.
Schwanstecher C; Schwanstecher M
Handb Exp Pharmacol; 2011; (203):1-33. PubMed ID: 21484565
[TBL] [Abstract][Full Text] [Related]
56. Beyond insulin replacement: addressing the additional needs of the diabetes patient.
Dailey G
Diabetes Obes Metab; 2008 Jul; 10 Suppl 2():83-97. PubMed ID: 18577160
[TBL] [Abstract][Full Text] [Related]
57. Clinical decisions. Management of type 2 diabetes.
Goldberg RB; Holman R; Drucker DJ
N Engl J Med; 2008 Jan; 358(3):293-7. PubMed ID: 18199869
[No Abstract] [Full Text] [Related]
58. Current and emerging therapies: an overview of incretin-based therapy in the management of type 2 diabetes.
Pratley RE
J Am Acad Nurse Pract; 2008 Nov; 20 Suppl 1():7-11. PubMed ID: 19402254
[No Abstract] [Full Text] [Related]
59. GLP-1 agonists and dipeptidyl-peptidase IV inhibitors.
Gallwitz B
Handb Exp Pharmacol; 2011; (203):53-74. PubMed ID: 21484567
[TBL] [Abstract][Full Text] [Related]
60. Incretin enhancers and the evolution of antihyperglycemic therapy in type 2 diabetes.
Inzucchi SE
Endocrinol Metab Clin North Am; 2007 Dec; 36 Suppl 2 Incretin():2-17. PubMed ID: 18405144
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
